.png?width=2400&height=263&name=Emergent-BioServices_CMYK_Logo-Tagline-Lockup%20(2).png "Emergent BioSolutions CDMO"){kind=logo}
08.17.2022
How CDMOs Can Support Nanoparticles for Gene Therapy, Immuno-Oncology and Vaccines
Nanoparticles have experienced increasing demand in recent years in biopharmaceutical formulations, owing to their utility for...
03.21.2022
Four Key Considerations to Help Prepare for the Next Public Health Threat
As a CDMO, Emergent has been working for more than two decades to develop, manufacture, and deliver protections against public...
03.11.2022
The Path to Reemergence
Dino Muzzin, senior vice president of manufacturing operations at Emergent BioSolutions recently shared his insights with Pharma...
09.14.2021
Emergent BioSolutions Secures Multi-Year Development and Manufacturing Agreement with Providence Therapeutics for its mRNA COVID-19 Vaccine Candidate, PTX-COVID19-B
- Total baseline value for Emergent is approximately $90 million USD, further expanding the collaboration between the companies,...
02.13.2021
Emergent Enters Into a New CDMO Agreement with Providence Therapeutics to Provide Fill/Finish Drug Product Manufacturing
Emergent has entered into a new CDMO agreement with Providence Therapeutics to provide fill/finish drug product manufacturing...
01.25.2021
Humanigen and Emergent BioSolutions Announce Contract Development and Manufacturing Agreement for Phase 3 COVID-19 Therapeutic Candidate Lenzilumab™
GAITHERSBURG, MD. and BURLINGAME, CA. – Jan. 25, 2021—Emergent BioSolutions Inc.(NYSE:EBS) (Emergent) andHumanigen, Inc....